Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
European pragmatic randomized trial of antiplatelet and/or lipid-lowering treatment in covert brain infarction
2025-521452-30-01Phase 3Authorised
- Sponsor
- Central Denmark Region
- Start
- Oct 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of clopidogrel, atorvastatin, rosuvastatin and aspirin in covert brain infarction (CBI) (2 arms), sponsored by Central Denmark Region. Primary endpoints: Primary efficacy endpoint and Primary safety endpoint. Planned start Oct 2025; status: authorised.
02
Drugs
clopidogrelatorvastatinrosuvastatinaspirin
03
Conditions
covert brain infarction (CBI)
Beyond the preview
Go deeper on 2025-521452-30-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521452-30-01.